FTC Claims Martin Shkreli Live‑Streamed Violation of Lifetime Pharma Ban

The Federal Trade Commission disclosed Wednesday that former biotech mogul Martin Shkreli aired a live video that appears to breach the lifetime ban prohibiting his participation in the pharmaceutical industry. The agency said the footage, uploaded to a public streaming platform, captured Shkreli handling drug‑related documents and talking about possible business arrangements, actions that directly violate the settlement terms.

Shkreli first rose to national prominence in 2015 when his firm, Turing Pharmaceuticals, hiked the price of Daraprim—a drug used to treat a parasitic infection—by more than 4,000 percent. The steep increase provoked widespread outrage and triggered a criminal probe that later uncovered a separate securities‑fraud scheme. In 2018, a federal jury found him guilty of securities fraud, resulting in a seven‑year prison sentence.

Alongside the criminal punishment, the FTC reached a civil settlement that imposes a permanent prohibition on Shkreli’s involvement in any capacity within the pharmaceutical sector. The order bars him from manufacturing, marketing, or even consulting on drug products and requires him to abstain from any activity that could sway the prescription‑medicine market.

The FTC’s release notes that the livestream—recorded in early August—depicted Shkreli seated at a desk surrounded by medical‑industry literature. He spoke candidly about "getting back into the game" and mentioned contacts at a venture‑capital firm that funds biotech startups. The video was posted to a widely used live‑streaming site and stayed online for several hours before being taken down after a takedown request.

In reaction, the commission said it is weighing a suite of enforcement options, including further monetary fines and possibly asking a court to impose tighter supervisory conditions. The FTC stressed that breaches of lifetime bans are uncommon but are treated seriously, as they erode the agency’s capacity to shield consumers from fraud and abusive conduct.

The episode revives discussion about how effectively regulators can monitor high‑profile figures who operate chiefly online. Consumer advocates argue the Shkreli case underscores the need for stronger digital surveillance tools, while civil‑liberties groups warn against governmental overreach. Whatever the FTC’s next move, it will likely set a benchmark for addressing similar violations in an increasingly connected marketplace.